Aquestive Therapeutics: Advancing Anaphylm and Strategic Preparations Support Buy Rating

Analyst Roanna Ruiz of Leerink Partners maintained a Buy rating on Aquestive Therapeutics, with a price target of $10.00.

Roanna Ruiz’s rating is based on several promising developments at Aquestive Therapeutics. The company reported financial results that align closely with expectations and maintained its revenue guidance for the fiscal year. A key factor in the Buy rating is the progress of Anaphylm, their leading product, which is advancing well through the FDA review process. The preparations for the advisory committee are also moving forward, with the first mock AdCom successfully completed, indicating strong management execution.
Additionally, Aquestive is actively preparing for the commercial launch of Anaphylm, including scaling up pre-commercial activities and expanding their market access team. The company’s patient-first approach, particularly their day-one cash pay program, aims to circumvent potential payer barriers and ensure immediate patient access. With a solid cash position and ongoing efforts to explore financing options, including international expansion, Aquestive is well-positioned for future growth, supporting the Buy recommendation.

In another report released on August 13, Lake Street also maintained a Buy rating on the stock with a $8.00 price target.

AQST’s price has also changed moderately for the past six months – from $3.470 to $4.010, which is a 15.56% increase.